Compare OLN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLN | VRDN |
|---|---|---|
| Founded | 1892 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 1994 | 2014 |
| Metric | OLN | VRDN |
|---|---|---|
| Price | $24.70 | $28.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | $23.43 | ★ $40.92 |
| AVG Volume (30 Days) | ★ 2.7M | 1.0M |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,780,800,000.00 | $5,706,000.00 |
| Revenue This Year | $1.55 | $4.67 |
| Revenue Next Year | $3.49 | $331.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.68 | N/A |
| 52 Week Low | $17.66 | $9.90 |
| 52 Week High | $27.35 | $34.29 |
| Indicator | OLN | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 45.38 |
| Support Level | $22.65 | $26.31 |
| Resistance Level | $26.81 | $33.71 |
| Average True Range (ATR) | 1.41 | 1.58 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 52.55 | 52.01 |
Olin Corp manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on the product type. The Chlor alkali products and Vinyls segment, which generates the majority of revenue, sells chlorine and caustic soda, which are used in a variety of industries including cosmetics, textiles, crop protection, and fire protection products. The Epoxy segment sells epoxy resins used in paints and coatings. The Winchester segment sells sporting ammunition and ammunition accessories under the Winchester brand. The majority of revenue comes from the United States.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).